keyword
MENU ▼
Read by QxMD icon Read
search

Tamoxifen aromatase

keyword
https://www.readbyqxmd.com/read/27894075/mammographic-density-a-potential-monitoring-biomarker-for-adjuvant-and-preventative-breast-cancer-endocrine-therapies
#1
REVIEW
Michael S Shawky, Hilary Martin, Honor J Hugo, Thomas Lloyd, Kara L Britt, Andrew Redfern, Erik W Thompson
Increased mammographic density (MD) has been shown beyond doubt to be a marker for increased breast cancer risk, though the underpinning pathobiology is yet to be fully elucidated. Estrogenic activity exerts a strong influence over MD, which consequently has been observed to change predictably in response to tamoxifen anti-estrogen therapy, although results for other selective estrogen receptor modulators and aromatase inhibitors are less consistent. In both primary and secondary prevention settings, tamoxifen-associated MD changes correlate with successful modulation of risk or outcome, particularly among pre-menopausal women; an observation that supports the potential use of MD change as a surrogate marker where short-term MD changes reflect longer-term anti-estrogen efficacy...
November 21, 2016: Oncotarget
https://www.readbyqxmd.com/read/27852186/supportive-care-of-women-with-breast-cancer-key-concerns-and-practical-solutions
#2
Nicholas Zdenkowski, Stephanie Tesson, Janine Lombard, Melanie Lovell, Sandra Hayes, Prudence A Francis, Haryana M Dhillon, Frances M Boyle
Patients diagnosed with breast cancer may have supportive care needs for many years after diagnosis. High quality multidisciplinary care can help address these needs and reduce the physical and psychological effects of breast cancer and its treatment. Ovarian suppression and extended endocrine therapy benefits are associated with vasomotor, musculoskeletal, sexual and bone density-related side effects. Aromatase inhibitor musculoskeletal syndrome is a common reason for treatment discontinuation. Treatment strategies include education, exercise, simple analgesia and a change to tamoxifen or another aromatase inhibitor...
November 21, 2016: Medical Journal of Australia
https://www.readbyqxmd.com/read/27848887/metabolism-and-toxicological-implications-of-commonly-used-chemopreventive-drugs-against-breast-cancer-carcinogenesis
#3
Aliyu Muhammad, Mohammed Auwal Ibrahim, Ochuko Lucky Erukainure, Ibrahim Malami, Hadiza Sani, Hafsat Abdullahi Mohammed
BACKGROUND: Breast cancer has been reported to be among the frequently diagnosed cancer in women worldwide despite advances in early detection and treatment. Several drugs are currently used for chemoprevention as a result of a number of drawbacks associated with breast cancer therapy. AIM: This review focuses on the metabolism and toxicological implications of these drugs against breast cancer/carcinogenesis. METHODOLOGY: Relevant articles on the commonly used anti-breast cancer drugs (raloxifene, tamoxifen, anastrozole, letrozole and exemestane) used in chemoprevention were searched using the major scientific databases including Scopus, Embase, PubMed/ Medline, Sciencedirect and Google Scholar...
November 16, 2016: Current Drug Metabolism
https://www.readbyqxmd.com/read/27843622/review-of-hormone-based-treatments-in-postmenopausal-patients-with-advanced-breast-cancer-focusing-on-aromatase-inhibitors-and-fulvestrant
#4
REVIEW
Iben Kümler, Ann S Knoop, Christina A R Jessing, Bent Ejlertsen, Dorte L Nielsen
BACKGROUND: Endocrine therapy constitutes a central modality in the treatment of oestrogen receptor (ER)-positive advanced breast cancer. PURPOSE: To evaluate the evidence for endocrine treatment in postmenopausal patients with advanced breast cancer focusing on the aromatase inhibitors, letrozole, anastrozole, exemestane and fulvestrant. METHODS: A review was carried out using PubMed. Randomised phase II and III trials reporting on ≥100 patients were included...
2016: ESMO Open
https://www.readbyqxmd.com/read/27823654/aromatase-inhibitors-in-premenopause-great-expectations-fulfilled
#5
REVIEW
Rosalba Torrisi, Selene Rota, Agnese Losurdo, Monica Zuradelli, Giovanna Masci, Armando Santoro
Tamoxifen and GnRH analogues (GnRHa) represent the mainstay of endocrine manipulations in premenopausal women. The estrogen blockade obtained by aromatase inhibitors (AIs) plus GnRHa suppresses circulating estrogens more deeply than tamoxifen plus GnRHa. Retrospective and prospective evidence confirm a substantial activity for AIs and GnRHa in locally advanced and metastatic breast cancer. In early breast cancer inconsistent evidence emerged from 2 large randomized studies with anastrozole performing as tamoxifen in terms of DFS, but significantly worse as of OS while exemestane outperformed tamoxifen as of DFS particularly in very young and high-risk women...
November 2016: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/27817058/aromatase-inhibitor-induced-carpal-tunnel-syndrome-prevalence-in-daily-practice
#6
Labidi Soumaya, Mejri Nesrine, El Benna Houda, Afrit Mehdi, Lakhdhar Sarra, Boussen Hamouda
INTRODUCTION: We aim to evaluate prevalence and characteristics of CTS in routine daily practice over a 5-year period, with a review of the literature. METHODS: Patients treated with endocrine therapy (441) were retrospectively analyzed looking for CTS cases in aromatase inhibitors (219, 49.6%) and in tamoxifen (222, 50.3%) patients. We described patient's characteristics and CTS management. We also reviewed the literature reporting CTS in aromatase inhibitors clinical trials...
December 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/27809310/downregulation-of-microrna-27b-3p-enhances-tamoxifen-resistance-in-breast-cancer-by-increasing-nr5a2-and-creb1-expression
#7
Jiang Zhu, Zhengzhi Zou, Peipei Nie, Xiaoni Kou, Baoyan Wu, Songmao Wang, Zhangjun Song, Jianjun He
Estrogen-dependent breast cancer is often treated with the aromatase inhibitors or estrogen receptor (ER) antagonists. Tamoxifen as a major ER antagonist is usually used to treat those patients with ERα-positive breast cancer. However, a majority of patients with ERα positive fail to respond to tamoxifen due to the presence of intrinsic or acquired resistance to the drug. Altered expression and functions of microRNAs (miRNAs) have been reportedly associated with tamoxifen resistance. In this study, we investigated the role of miR-27b-3p in resistance of breast cancer to tamoxifen...
November 3, 2016: Cell Death & Disease
https://www.readbyqxmd.com/read/27801672/antiestrogen-use-reduces-risk-of-cervical-neoplasia-in-breast-cancer-patients-a-population-based-study
#8
Chia-Jung Hsieh, Mun-Kun Hong, Pau-Chung Chen, Jen-Hung Wang, Tang-Yuan Chu
Estrogen has been proven to be a necessity for cervical carcinogenesis by transgenic mice studies. To determine whether long-term antiestrogens use could reduce the incidence of cervical neoplasia, a population-based cohort of 42,940 breast cancer patients with and without antiestrogen therapy were identified from the Taiwan National Health Insurance Database. All patients were followed for the most severe form of cervical neoplasia or until death. Their risks of cervical neoplasia were compared with Cox regression analysis and adjusted for age, Pap smear density and chemotherapy...
October 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/27785653/ovarian-suppression-in-combination-endocrine-adjuvant-therapy-in-premenopausal-women-with-early-breast-cancer
#9
REVIEW
Rowan T Chlebowski, Kathy Pan, Nananda F Col
PURPOSE: The benefits of adding ovarian suppression to either tamoxifen or aromatase inhibitors as adjuvant breast cancer therapy in premenopausal women are controversial. Therefore, we performed a systematic literature review and meta-analysis of relevant randomized trials. METHODS: We identified and combined four qualifying trials reporting disease-free survival (DFS) and overall survival (OS) using meta-analysis. RESULTS: Combining ABCSG-12, SOFT, and TEXT studies, there were 65 fewer DFS events (HR 0...
October 26, 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27780311/initiation-of-and-adherence-to-tamoxifen-and-aromatase-inhibitor-therapy-among-elderly-women-with-ductal-carcinoma-in-situ
#10
Hui Zhao, Nainan Hei, Yiling Wu, Winston Chan, Xiudong Lei, Carrie Cameron, Shine Chang, Mariana Chavez-MacGregor, Sharon H Giordano
BACKGROUND: The National Surgical Adjuvant Breast and Bowel Project B35 and International Breast Cancer Intervention Studies II Ductal Carcinoma In Situ trials showed similar treatment effects of anastrozole and tamoxifen in reducing cancer recurrence risk among ductal carcinoma in situ (DCIS) patients. Studies have shown low levels of hormone therapy drug initiation for DCIS patients, but the current body of literature lacks information on the 5-year adherence rates for these drugs from population-based studies...
October 25, 2016: Cancer
https://www.readbyqxmd.com/read/27721710/memory-and-spatial-cognition-in-breast-cancer-patients-undergoing-adjuvant-endocrine-therapy
#11
Ute Berndt, Bernd Leplow, Robby Schoenfeld, Tilmann Lantzsch, Regina Grosse, Christoph Thomssen
INTRODUCTION: It is generally accepted that estrogens play a protective role in cognitive function. Therefore, it can be expected that subtotal estrogen deprivation following aromatase inhibition will alter cognitive performance. METHODS: In a cross-sectional study we investigated 80 postmenopausal women with breast cancer. Memory and spatial cognition were compared across 4 treatment groups: tamoxifen only (TAM, n = 22), aromatase inhibitor only (AI, n = 22), TAM followed by AI ('SWITCH group', n = 15), and patients with local therapy (LT) only (surgery and radiation, n = 21)...
August 2016: Breast Care
https://www.readbyqxmd.com/read/27711920/association-of-adjuvant-tamoxifen-and-aromatase-inhibitor-therapy-with-contralateral-breast-cancer-risk-among-us-women-with-breast-cancer-in-a-general-community-setting
#12
Gretchen L Gierach, Rochelle E Curtis, Ruth M Pfeiffer, Maeve Mullooly, Estelle A Ntowe, Robert N Hoover, Sarah J Nyante, Heather Spencer Feigelson, Andrew G Glass, Amy Berrington de Gonzalez
Importance: Within 10 years after breast cancer diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC). Randomized trials have found that therapy including tamoxifen citrate and aromatase inhibitors (AIs) reduces CBC risk. But little is known about the magnitude and duration of protective associations within the context of real-world clinical management settings, where varying durations of and gaps in treatment are common. Objective: To determine the association between adjuvant tamoxifen and AI therapy and CBC risk within a general community setting...
October 6, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27706436/health-care-factors-associated-with-survival-among-women-with-breast-cancer-on-hormone-therapy-in-rio-de-janeiro-brazil-2004-2010
#13
Cláudia de Brito, Margareth Crisóstomo Portela, Mauricio Teixeira Leite de Vasconcellos
Objectives To better understand the role that health care plays in breast cancer survival by investigating the effects that hormone therapy adherence and other select health care variables, adjusted for clinical and sociodemographic factors, had among a population of women in Rio de Janeiro, Brazil. Methods This was a longitudinal study based on secondary data of 5 861 women treated with hormone therapy (tamoxifen or aromatase inhibitors) at the National Cancer Institute of Brazil (INCA), from 1 January 2004 - 29 October 2010...
June 2016: Revista Panamericana de Salud Pública, Pan American Journal of Public Health
https://www.readbyqxmd.com/read/27701383/risk-of-hospitalisation-and-death-due-to-bone-fractures-after-breast-cancer-a-registry-based-cohort-study
#14
Edoardo Colzani, Mark Clements, Anna L V Johansson, Annelie Liljegren, Wei He, Judith Brand, Jan Adolfsson, Tommy Fornander, Per Hall, Kamila Czene
BACKGROUND: Bone fractures may have an impact on prognosis of breast cancer. The long-term risks of bone fracture in breast cancer patients have not been thoroughly studied. METHODS: Poisson regression was used to investigate the incidence of hospitalisation due to bone fracture comparing women with and without breast cancer based on Swedish National registers. Cox regression was used to investigate the risk of being hospitalised with bone fracture, and subsequent risk of death, in a regional cohort of breast cancer patients...
November 22, 2016: British Journal of Cancer
https://www.readbyqxmd.com/read/27693889/the-risk-of-myocardial-infarction-with-aromatase-inhibitors-relative-to-tamoxifen-in-post-menopausal-women-with-early-stage-breast-cancer
#15
Husam Abdel-Qadir, Eitan Amir, Hadas D Fischer, Longdi Fu, Peter C Austin, Paula J Harvey, Paula A Rochon, Douglas S Lee, Geoffrey M Anderson
BACKGROUND: Aromatase inhibitors (AIs) may increase cardiovascular risk relative to tamoxifen in post-menopausal women with breast cancer. This risk has not been well-quantified outside of clinical trials. METHODS: Observational population-based cohort study of women aged >55 years diagnosed with stage I-III breast cancer between 2005 and 2010. Women treated with AIs or tamoxifen were followed to March 2012. The primary outcome was hospitalisation for myocardial infarction (MI)...
September 29, 2016: European Journal of Cancer
https://www.readbyqxmd.com/read/27680018/endocrine-therapy-and-urogenital-outcomes-among-women-with-a-breast-cancer-diagnosis
#16
Suzanne N Landi, Kemi M Doll, Jeannette T Bensen, Laura Hendrix, Carey K Anders, Jennifer M Wu, Hazel B Nichols
PURPOSE: Endocrine therapy for breast cancer can exacerbate menopausal symptoms. The association between endocrine therapy and common pelvic floor disorders including urinary incontinence has rarely been evaluated. We examined urogenital and sexual side effects among women with a breast cancer diagnosis, comparing endocrine therapy users to nonusers. METHODS: Urogenital and sexual symptoms were self-reported during the enrollment interview within the University of North Carolina Cancer Survivorship Cohort...
September 28, 2016: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/27663436/impact-of-androgen-receptor-expression-in-fluoxymesterone-treated-estrogen-receptor-positive-metastatic-breast-cancer-refractory-to-contemporary-hormonal-therapy
#17
Miho Kono, Takeo Fujii, Genevieve Ray Lyons, Lei Huo, Roland Bassett, Yun Gong, Meghan Sri Karuturi, Debu Tripathy, Naoto T Ueno
PURPOSE: The purpose of this study is to evaluate survival outcome in patients with hormone receptor (HR)-positive (+) metastatic breast cancer (MBC) who received fluoxymesterone after disease progression while receiving contemporary hormonal therapy, as well as the association between estrogen receptor (ER)/androgen receptor (AR) status and survival outcome in these patients. METHODS: We retrospectively identified 103 patients treated with fluoxymesterone for HR + MBC from 2000 to 2014 and with at least one previous hormonal therapy in a metastatic setting...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27663434/prognostic-value-of-endocrine-treatment-related-symptoms-in-patients-with-breast-cancer-a-meta-analysis
#18
Qiufan Zheng, Wen Xia, Qianyi Lu, Ruoxi Hong, Ge Qin, Fei Xu, Tao Qin, Yanxia Shi, Zhongyu Yuan, Shusen Wang
PURPOSE: Endocrine therapy is associated with improved disease-free survival (DFS) in hormone receptor-positive breast cancer, but it is also associated with many adverse events. The aim of this study was to clarify the association between endocrine treatment-related symptoms and treatment efficacy in patients receiving adjuvant endocrine therapy. METHOD: EMBASE, Web of Science, PubMed, and CENTRAL databases were searched for studies that compared treatment efficacy between patients in whom adverse events did and did not occur during hormone therapy...
November 2016: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27606696/extended-adjuvant-endocrine-therapy-in-hormone-receptor-positive-early-breast-cancer
#19
Connor G O'Leary, Haley Ellis, Michaela Higgins
PURPOSE OF REVIEW: The risk of relapse associated with oestrogen receptor-positive early breast cancer persists for at least 15 years after diagnosis. Several large clinical trials have examined extended adjuvant endocrine therapy. RECENT FINDINGS: The MA.17 trial demonstrated improved disease-free survival (DFS) with use of letrozole for 5 years after some years of tamoxifen and an overall survival advantage for this approach in women with node-positive oestrogen receptor-positive cancer at diagnosis...
November 2016: Current Opinion in Oncology
https://www.readbyqxmd.com/read/27599040/persistence-to-5-year-hormonal-breast-cancer-therapy-a-french-national-population-based-study
#20
Pauline Bosco-Lévy, Jeremy Jové, Philip Robinson, Nicholas Moore, Annie Fourrier-Réglat, Julien Bezin
BACKGROUND: Non-persistence to oral hormonal therapy (HT) in breast cancer (BC) is an emerging health issue, and estimations vary according to the population selected and/or the statistical method applied. This study aimed to estimate non-persistence over 5 years to HT in an unselected sample of women with BC using a French national population-based database and accounting for competing risks. METHODS: A retrospective cohort of 600 women initiating a HT between 2006 and 2007 was constituted using a representative sample of the French national healthcare insurance system database...
October 11, 2016: British Journal of Cancer
keyword
keyword
30009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"